title: Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues.
abstract: BACKGROUND
  A new era has dawned in the treatment of chronic hepatitis C (HCV) virus with the use of direct-acting antiviral medications augmenting combination therapy. Unfortunately, the significant impact of improvements may not be realized if antiviral treatment is not expanded to include a larger proportion of patients, many of whom have coexisting mental health and/or substance abuse issues and have been historically deferred from treatment.
  
  
  METHODS
  We reviewed the extent literature on HCV treatment for individuals with co-occurring mental health and/or substance abuse issues.
  
  
  RESULTS
  A number of empirically-based arguments exist in favor of treating HCV-infected individuals with mental health and/or substance abuse issues within the context of multidisciplinary team approaches. Integrated, collaborative, or hybrid models of care are just a few examples of multidisciplinary approaches that can combine the care of HCV treating providers with mental health and/or addictions providers to safely and effectively treat these patients. Collectively, these arguments and the empirical evidence that supports them, provides a strong rationale for why expanding antiviral therapy to these patients is critical and timely.
  
  
  CONCLUSIONS
  A decade of evidence suggests that HCV-infected individuals with mental health and/or substance abuse issues can safely and effectively undergo antiviral treatment when delivered through multidisciplinary care settings. Multidisciplinary approaches that combine HCV treating providers with mental health, addictions, and other support systems can facilitate preparation and successful treatment of these patients on antiviral therapy.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
authors.forename: Jason E
authors.initials: JE
authors.lastname: Bonner
authors.forename: A Sidney
authors.initials: AS
authors.lastname: Barritt
authors.forename: Michael W
authors.initials: MW
authors.lastname: Fried
authors.forename: Donna M
authors.initials: DM
authors.lastname: Evon
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015897:Comorbidity; D003657:Decision Making; D005260:Female; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D008297:Male; D016743:Mental Competency; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D008603:Mental Health; D020380:Needs Assessment; D010349:Patient Compliance / Q000706:statistics & numerical data; D010353:Patient Education as Topic / Q000458:organization & administration; D018570:Risk Assessment; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D014481:United States
chemical_list: D000998:Antiviral Agents